Literature DB >> 2126587

Inhibitors of lymphocyte activation secreted by human melanoma cell lines.

D Giacomoni1, S Ben-Efraim, F Najmabadi, S Dray.   

Abstract

The concentrated supernatants of nine human melanoma cell line cultures were analyzed for the presence of factors that inhibit in vitro immunological reactions. All cell lines secreted a factor that inhibited LPS-induced proliferation of murine B cells; eight cell lines released a factor that inhibited PHA-induced proliferation of murine T cells; all of the three cell lines investigated secreted a factor that inhibited the allogeneic stimulation of BALB/c spleen cells by mitomycin-C-treated C57BL spleen cells. Further analysis of the M21 cell supernatant indicated that its continuous presence was required for the inhibition of the PHA but not of the LPS response suggesting a different mechanism of action. High levels of PHA, but not of LPS, could overcome the inhibitory effect of M21 supernatants. Fractionation of M21 supernatants by sucrose gradient centrifugation, DEAE chromatography and gel filtration suggested that the anti-PHA and the anti-LPS activities were due to different factors. These factors differed from a serine proteinase inhibitor that is also released by M21 cells. Since these inhibitory factors may have a role in protecting a melanoma tumor from attack by the immune system of the host, their consideration may be helpful in designing protocols for therapy which include methods to boost the antitumor responses of the host.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2126587     DOI: 10.1007/bf02987106

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  17 in total

1.  Serine proteinase inhibitors produced by human melanoma cell lines.

Authors:  D Giacomoni; F Najmabadi; S Dray
Journal:  Tumour Biol       Date:  1990

2.  Deficiency in immunocompetence of mice cured from large MOPC-315 plasmacytomas by melphalan therapy.

Authors:  S Shoval; R Ophir; S Ben-Efraim
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 3.  The membrane attack complex of complement.

Authors:  H J Müller-Eberhard
Journal:  Annu Rev Immunol       Date:  1986       Impact factor: 28.527

4.  Immunoregulatory factors derived from human tumors. II. Partial purification and further immunobiochemical characterization of a human sarcoma-derived immunosuppressive factor expressing HLA-DR and immunoglobulin-related determinants.

Authors:  J A Roth; B A Osborne; R S Ames
Journal:  J Immunol       Date:  1983-01       Impact factor: 5.422

5.  The major urinary protease inhibitor: simplified purification and characterization.

Authors:  B J Bromke; F Kueppers
Journal:  Biochem Med       Date:  1982-02

6.  Detection of an inhibitor of cell division in cultures of tumour cells with immunosuppressive activity in vitro.

Authors:  J Werkmeister; R Zbroja; W McCarthy; P Hersey
Journal:  Clin Exp Immunol       Date:  1980-04       Impact factor: 4.330

7.  Effect of low-dose cyclophosphamide therapy on specific and nonspecific T cell-dependent immune responses of spleen cells from mice bearing large MOPC-315 plasmacytomas.

Authors:  J A Wise; M B Mokyr; S Dray
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

8.  Identification and characterization of a tumor-derived immunosuppressive glycoprotein from murine melanoma K-1735.

Authors:  J B Putnam; J A Roth
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

9.  An inhibitor of lymphocyte proliferation produced by a human colonic adenocarcinoma cell line in culture.

Authors:  J S Whitehead; Y S Kim
Journal:  Cancer Res       Date:  1980-01       Impact factor: 12.701

10.  Tumor-derived suppressor factors (TDSFs) in normal and neoplastic colon and rectum.

Authors:  J G Hoagland; S Scoggin; R Giavazzi; D Campbell; K Kanellopoulos; J M Jessup
Journal:  J Surg Res       Date:  1986-05       Impact factor: 2.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.